Mutations in SARS-CoV-2 Leading to Antigenic Variations in Spike Protein: A Challenge in Vaccine Development

Abstract

Objectives The spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has been unprecedentedly fast, spreading to more than 180 countries within 3 months with variable severity. One of the major reasons attributed to this variation is genetic mutation. Therefore, we aimed to predict the mutations in the spike protein (S) of the SARS-CoV-2 genomes available worldwide and analyze its impact on the antigenicity. Materials and Methods Several research groups have generated whole genome sequencing data which are available in the public repositories. A total of 1,604 spike proteins were extracted from 1,325 complete genome and 279 partial spike coding sequences of SARS-CoV-2 available in NCBI till May 1, 2020 and subjected to multiple sequence alignment to find the mutations corresponding to the reported single nucleotide polymorphisms (SNPs) in the genomic study. Further, the antigenicity of the predicted mutations inferred, and the epitopes were superimposed on the structure of the spike protein. Results The sequence analysis resulted in high SNPs frequency. The significant variations in the predicted epitopes showing high antigenicity were A348V, V367F and A419S in receptor binding domain (RBD). Other mutations observed within RBD exhibiting low antigenicity were T323I, A344S, R408I, G476S, V483A, H519Q, A520S, A522S and K529E. The RBD T323I, A344S, V367F, A419S, A522S and K529E are novel mutations reported first time in this study. Moreover, A930V and D936Y mutations were observed in the heptad repeat domain and one mutation D1168H was noted in heptad repeat domain 2. Conclusion S protein is the major target for vaccine development, but several mutations were predicted in the antigenic epitopes of S protein across all genomes available globally. The emergence of various mutations within a short period might result in the conformational changes of the protein structure, which suggests that developing a universal vaccine may be a challenging task.

Novel and emerging mutations of SARS-CoV-2: Biomedical implications

“…At least one of the serotypes must have a D614G mutation and associated mutations that alter the interaction of neutralizing antibodies. These mutations change immunogenicity and the structure and sequence of immunodominant linear and conformational epitopes and escape capability from humoral immune pressure, otherwise retain the strong binding affinity toward ACE2 [104] , [105] .…”

Third update on possible animal sources for human COVID‐19

“…Subsequently, the same mutated viruses were also detected in humans who were in close contact with the mink 25,27 . During vaccine development, it is crucial to monitor any viral changes which may occur at vaccine target sites, as these may render a novel vaccination product ineffective 28 . At this point, scientists suggest that the mink‐specific SARS‐CoV‐2 mutations identified so far will not jeopardize the effectiveness of potential COVID‐19 vaccines 29 …”

BCG, muramylpeptides, trained immunity (part II): a low molecular weight alternative to multicomponent bacterial immunostimulants for prevention of respiratory infections during a pandemic

“…Мнения специалистов по поводу антигенной изменчивости SARS-CoV-2, в частности его Spike(S)-протеина (главной молекулярной мишени вакцин против нового коронавируса), существенно разнятся. Это отражается как оптимистичными [8], так и весьма сдержанными [9] прогнозами в отношении долгосрочной эффективности разрабатываемых вакцин против SARS-CoV-2. Остается во многих аспектах открытым вопрос, в какой степени уже доказанная иммуногенность создаваемых вакцин обеспечит их клиническую действенность.…”